DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Lucas KJ, Lopez P, Lawitz EJ. et al.
Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results.
Dig Liv Dis 2020;
52 (01) E38
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.